Testoluten®
The biologically active food supplement TESTOLUTEN® contains a complex of low molecular weight
peptides with a molecular weight of up to 5,000 Da, isolated from the tissues of the testes of young
animals - mature bulls.
TESTOLUTEN® is available in capsules with an active substance content of 10 mg.
TESTOLUTEN® peptides regulate metabolic processes in testicular cells, increase the reserve capac-
ity of the male reproductive system, have a beneficial effect on the adaptation processes of the body
in extreme conditions, and have antioxidant properties, regulating the processes of peroxidation in
testis tissues. Experimental studies have shown that peptides have a tissue-specific effect on the cells
of those tissues from which they are isolated. This allows us to assume the effectiveness of the use of
TESTOLUTEN® to restore the functions of the male reproductive system in case of its malfunctions
of various origins.
The climax is a transitional period of qualitative restructuring of the body in new age-related condi-
tions of the dynamic interaction of organs and systems to maintain the relative stability of homeo-
stasis. Essentially it is a physiological syndrome caused by age-related shifts in hormonal and general
metabolism and, above all, age-related extinction of the function of the gonads. In men, it occurs lat-
er than in women. It proceeds less noticeably and merges with the signs of old age. Symptoms of the
male physiological climax can be observed in different age groups and varying degrees of severity.
Changes in the functional state of the male reproductive glands play an important role for the male
body in this period. It is generally accepted that involutionary processes primarily affect the endocrine
function of the testicles.
The onset of atrophic processes in the interstitial tissue of the testicles with the involvement of glan-
dulocytes in the process can be detected already at the age of 30-40 years. At the age of 50-60 years
and older, the concentration of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testos-
terone, and estradiol ratios change significantly. Changes in the hormonal background and the associ-
ated restructuring of the mental and neurohumoral components of the copulatory cycle underlie the
extinction of the copulative function, which is manifested by a decrease in the frequency of sexual
intercourse, a reduction in libido, and weakening of erections. In this case, the increase in pathologi-
cal symptoms from the nervous, vascular and reproductive systems in men of the older age group are
accompanied by pathological male climax (2, 3). Medical treatment of the climax is necessary only for
those men in whom its manifestations significantly go beyond the physiological framework, leading to
a disorder of critical functional systems of the body. In such cases, treatment should be comprehen-
sive and include etiological, pathogenetic, and symptomatic components (1, 2, 3).
For the treatment of male climax, the following drugs are used:
- Hormonal drugs (methyltestosterone, testosterone propionate, sustanon-250, ambosex);
- Adaptogens (ginseng, extracts of Eleutherococcus, Leuzea, Rhodiolarosea, tinctures of aralia, zamani-
hi, saparal, pantocrine);
- Tranquilizers (elenium, seduxen, phenazepam, meprobamate, trioxazine);
- Antidepressants (clomipramine, melipramine);
- Vitamin therapy (vitamins B1, B6, B12);
- etc.
A clinical study of the effectiveness of TESTOLUTEN® was carried out at the Medical Center of the
St. Petersburg Institute of Bioregulation and Gerontology in the period from May to November 2011.
The clinical study involved 36 men aged 47 to 65 years with a diagnosis of male climax.
Patients complained of rapid fatigue, decreased physical and mental performance, weakened memo-
ry, emotional instability, increased sweating, irritability, and surges in blood pressure. Still, most men
paid particular attention to the appearance of sexual weakness.
Most of the patients did not previously seek medical help and independently took various medications
that help to level pathological reactions.
The patients were divided into 2 groups (Table 1). Patients in the control group (14 people) received
conventional therapy, excluding hormonal drugs.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.